{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:32:09Z","timestamp":1793320329111,"version":"4.5.0"},"reference-count":30,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2021,1,1]]},"DOI":"10.1001\/jamaoncol.2020.5945","type":"journal-article","created":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T17:44:16Z","timestamp":1605807856000},"page":"78","source":"Crossref","is-referenced-by-count":208,"title":["Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer"],"prefix":"10.1001","volume":"7","author":[{"given":"Emese","family":"Zsiros","sequence":"first","affiliation":[{"name":"Department of Gynecologic Oncology, Clinical Sciences Center, Roswell Park Comprehensive Cancer Center, Buffalo, New York"},{"name":"Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Lynam","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Clinical Sciences Center, Roswell Park Comprehensive Cancer Center, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristopher M.","family":"Attwood","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanmuga","family":"Chilakapati","sequence":"additional","affiliation":[{"name":"Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo Cortes","family":"Gomez","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Akers","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Clinical Sciences Center, Roswell Park Comprehensive Cancer Center, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashikant","family":"Lele","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Clinical Sciences Center, Roswell Park Comprehensive Cancer Center, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Frederick","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Clinical Sciences Center, Roswell Park Comprehensive Cancer Center, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunle","family":"Odunsi","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Clinical Sciences Center, Roswell Park Comprehensive Cancer Center, Buffalo, New York"},{"name":"Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"coi200087r1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"coi200087r2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.","volume":"348","author":"Zhang","year":"2003","journal-title":"N Engl J Med"},{"issue":"51","key":"coi200087r3","doi-asserted-by":"crossref","first-page":"18538","DOI":"10.1073\/pnas.0509182102","article-title":"Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.","volume":"102","author":"Sato","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"coi200087r4","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat Med"},{"issue":"17","key":"coi200087r5","doi-asserted-by":"crossref","first-page":"7875","DOI":"10.1073\/pnas.1003345107","article-title":"Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.","volume":"107","author":"Matsuzaki","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"coi200087r6","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ygyno.2018.11.017","article-title":"Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: analysis of KEYNOTE-028.","volume":"152","author":"Varga","year":"2019","journal-title":"Gynecol Oncol"},{"key":"coi200087r7","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1001\/jamaoncol.2019.3343","article-title":"Assessment of combined nivolumab and bevacizumab in relapsed ovarian cancer: a phase 2 clinical trial.","volume":"5","author":"Liu","year":"2019","journal-title":"JAMA Oncol"},{"issue":"5","key":"coi200087r8","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/cam4.106","article-title":"PD-1 as a potential target in cancer therapy.","volume":"2","author":"McDermott","year":"2013","journal-title":"Cancer Med"},{"issue":"7","key":"coi200087r9","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann Oncol"},{"issue":"5","key":"coi200087r10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"coi200087r11","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nm.3541","article-title":"Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors.","volume":"20","author":"Motz","year":"2014","journal-title":"Nat Med"},{"issue":"7","key":"coi200087r12","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrclinonc.2014.89","article-title":"Metronomics: towards personalized chemotherapy?","volume":"11","author":"Andr\u00e9","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"coi200087r13","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","article-title":"Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.","volume":"26","author":"Garcia","year":"2008","journal-title":"J Clin Oncol"},{"issue":"23","key":"coi200087r14","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"2","key":"coi200087r15","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"10","key":"coi200087r18","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/S0959-8049(03)00307-1","article-title":"An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer.","volume":"39","author":"Greimel","year":"2003","journal-title":"Eur J Cancer"},{"issue":"33","key":"coi200087r19","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.","volume":"25","author":"Burger","year":"2007","journal-title":"J Clin Oncol"},{"key":"coi200087r20","doi-asserted-by":"crossref","DOI":"10.1214\/ss\/1009213286","article-title":"Interval estimation for a binomial proportion.","author":"Brown","year":"2001","journal-title":"Statist Sci"},{"issue":"43","key":"coi200087r21","doi-asserted-by":"crossref","first-page":"17561","DOI":"10.1073\/pnas.1215397109","article-title":"Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy.","volume":"109","author":"Huang","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"coi200087r22","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients.","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"coi200087r23","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ygyno.2018.04.059","article-title":"Phase II study of pembrolizumab (Pembro) combined with pegylated liposomal doxorubicin (PLD) for recurrent platinum-resistant ovarian, fallopian tube or peritoneal cancer.","volume":"149","author":"Matulonis","year":"2018","journal-title":"Gynecol Oncol."},{"key":"coi200087r24","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ygyno.2019.04.043","article-title":"Phase II trial of pembrolizumab with cisplatin and gemcitabine in women with recurrent platinum-resistant ovarian cancer.","volume":"154","author":"Walsh","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"16","key":"coi200087r26","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1200\/JCO.19.02059","article-title":"Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG Oncology Study.","volume":"38","author":"Zamarin","year":"2020","journal-title":"J Clin Oncol"},{"key":"coi200087r27","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/jamaoncol.2019.1048","article-title":"Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma.","volume":"5","author":"Konstantinopoulos","year":"2019","journal-title":"JAMA Oncol"},{"issue":"19","key":"coi200087r28","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1200\/JCO.2016.72.1340","article-title":"Safety and clinical activity of the programmed death-ligand 1 inhibitor durvalumab in combination with poly (ADP-ribose) polymerase inhibitor olaparib or vascular endothelial growth factor receptor 1-3 inhibitor cediranib in women\u2019s cancers: a dose-escalation, phase I study.","volume":"35","author":"Lee","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"coi200087r29","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jamaoncol.2018.6258","article-title":"Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN Solid Tumor Trial.","volume":"5","author":"Disis","year":"2019","journal-title":"JAMA Oncol"},{"issue":"8","key":"coi200087r30","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1093\/annonc\/mdx229","article-title":"Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy.","volume":"28","author":"Roncolato","year":"2017","journal-title":"Ann Oncol"},{"key":"coi200087r16","year":"2018"},{"key":"coi200087r25","author":"Burger"},{"key":"coi200087r17","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Published November 27, 2017. Accessed March 1, 2019. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2773114\/jamaoncology_zsiros_2020_oi_200087_1609897954.35761.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T21:25:48Z","timestamp":1618435548000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2773114"}},"subtitle":["A Phase 2 Nonrandomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2020.5945","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1,1]]}}}